Full text
Earnings transcript
Read the complete earnings call transcript.
ALGN
Align Technology, Inc.
$178.1
6.05
(3.52%)
| Exchange: | NASDAQ |
| Market Cap: | 12.755B |
| Shares Outstanding: | 4.218M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Joseph Hogan | |||||
| Full Time Employees: | 21200 | |||||
| Address: |
| |||||
| Website: | https://www.aligntech.com |
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company’s operations are divided into two main business units: “Clear Aligner” and “Scanners and Services.” The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go. Additional non-case products include retention devices, fees for Invisalign training, and sales of ancillary items such as cleaning materials and adjustment tools used by dental practitioners during treatment. The Scanners and Services segment centers around the iTero scanner, a unified hardware platform offering various software applications for both restorative and orthodontic procedures. It supplies specialized restorative software to general dentists, prosthodontists, periodontists, and oral surgeons, as well as distinct software for orthodontists to manage digital patient records, perform diagnoses, and facilitate the fabrication of printed models and retainers. This segment also provides computer-aided design and manufacturing (CAD/CAM) services, along with supplementary products like disposable covers for the scanner wand and iTero models and dies. Furthermore, it includes third-party scanners and digital scan solutions, the Invisalign Outcome Simulator (a chair-side and cloud-based application for the iTero scanner), the Invisalign Progress Assessment tool, and TimeLapse technology, which enables clinicians to compare a patient’s historical 3D scans against current data. Align Technology distributes its products worldwide, with a strong presence in the United States, Switzerland, and China. Founded in 1997, the company is headquartered in Tempe, Arizona.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 3,862,260 | 3,999,012 | 4,034,964 |
| Gross Profit | 2,706,863 | 2,799,159 | 2,756,897 |
| EBITDA | 799,055 | 816,798 | 765,874.955 |
| Operating Income | 643,338 | 607,628 | 616,216 |
| Net Income | 445,053 | 421,362 | 410,351 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 6,083,877 | 6,214,600 | 6,233,693 |
| Total Liabilities | 2,453,388 | 2,362,615 | 2,184,546 |
| Total Stockholders Equity | 3,630,489 | 3,851,985 | 4,049,147 |
| Total Debt | 126,619 | 119,277 | 82,507 |
| Cash and Cash Equivalents | 937,438 | 1,043,887 | 1,094,908 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 785,776 | 738,231 | 593,223 |
| Capital Expenditure | -177,716 | -115,580 | 0 |
| Free Cash Flow | 608,060 | 622,651 | 593,223 |
| Net Income | 445,053 | 421,362 | 410,351 |
| Net Change in Cash | -3,836 | 106,444 | 51,223 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 4,841,765.987 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 4,940,171.266 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 4,890,000 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 1,049,982.740 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 1,071,322.856 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 1,060,442.742 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 1,130,034.030 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 1,159,980.935 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,144,712.775 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 2,128,178.328 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,171,431.964 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 2,149,379.391 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 15.770 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 15.980 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 15.570 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 5 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 1 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Strong Revenue Performance: ALGN has demonstrated consistent revenue growth as per historical income statements, supported by robust demand in the dental and orthodontic solutions market (evident from revenue product segments). This aligns with industry trends in the healthcare sector focusing on innovative dental technologies.
- Healthy Profitability Metrics: Key metrics such as gross profit margin TTM and net profit margin TTM indicate efficient cost management and strong profitability, positioning ALGN favorably against industry averages (industry_avg_priceToEarningsRatioTTM).
- Solid Cash Flow Generation: Positive free cash flow (as per cash flow statements) and a high free cash flow yield TTM reflect ALGN’s ability to generate cash for reinvestment or shareholder returns, underpinned by strong operating cash flow figures.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates ALGN intrinsic value between $122.17 – $239.86 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about ALGN valuation
Is Align Technology, Inc. (ALGN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Align Technology, Inc. (ALGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is ALGN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether ALGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is ALGN’s P/E ratio?
You can see ALGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for ALGN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is ALGN a good long-term investment?
Whether ALGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
ALGN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
3.52
Trading Metrics:
| Open: | 174.51 | Previous Close: | 172.05 | |
| Day Low: | 172.66 | Day High: | 179.65 | |
| Year Low: | 122 | Year High: | 208.31 | |
| Price Avg 50: | 172.85 | Price Avg 200: | 158.81 | |
| Volume: | 957520 | Average Volume: | 1.151M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeALGN full analysis
Welcome to MARKETSNAP’s SWOT analysis for Align Technology, the company behind some of the most innovative dental and orthodontic solutions out there, including the well-known Invisalign system. If you’re a long-term investor looking to sink your teeth into a company with a unique spot in the healthcare tech space, you’ve come to the right place. Today, we’re diving deep into Align Technology’s strengths, weaknesses, opportunities, and threats, while also unpacking recent performance, key financials, and what’s driving the stock. So,…
